SAMHSA’s new Treatment Improvement Protocol 63, “Medications for Opioid Use Disorder,” helps behavioral healthcare professionals broaden their understanding of the three FDA-approved medications—methadone, naltrexone, and buprenorphine—used to help treat Americans with opioid use disorder, as well as the other strategies and services needed to support recovery for people with opioid use disorder.
TIP 63 had significant input from researchers, clinicians, and information specialists affiliated with the Alcohol & Drug Abuse Institute and the Pacific NW Node of NIDA's Clinical Trials Network (CTN). Ron Jackson, MSW, LICSW and Andrew Saxon, MD served on the Expert Panel to help develop the TIP via a consensus-driven, collaborative process that blends evidence-based, best, and promising practices with the panel’s expertise and combined wealth of experience.
In addition, field reviewers for this TIP included Meg Brunner, MLIS from ADAI and the CTN Dissemination Library, Alison Newman, MPH (ADAI) and Mary Catlin, RN, MPH, CIC, (DOH and ADAI). The field review allows people who work in addiction, mental health, and adjacent fields to gauge the TIP’s relevance, utility, accuracy, and accessibility.
Download TIP 63 or order print copies online: http://bit.ly/2ExvUkz
